Adam Daunton

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both

Nicholas D. James, Sarah Pirrie, Ann Pope et al. · JAMA Oncology · 2016 · 88 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747).

Nicholas D. James, Sarah Pirrie, Darren Barton et al. · Journal of Clinical Oncology · 2013 · 27 citations

Medicine, Oncology, Pharmacotherapy +17

British Association of Dermatologists guidelines for the management of adults with delusional infestation 2022

Alia Ahmed, Andrew Affleck, Janet Angus et al. · British Journal of Dermatology · 2022 · 27 citations · Full text

Medicine, Dermatology, Dermatopathology +2

Cost‐effectiveness of zoledronic acid and strontium‐89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate‐refractory prostate cancer: results from the <scp>TRAPEZE</scp> trial ( <scp>ISRCTN</scp> 12808747)

Lazaros Andronis, Ilias Goranitis, Sarah Pirrie et al. · British Journal of Urology · 2016 · 17 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Readability assessment of the British Association of Dermatologists’ patient information leaflets

William Hunt, J. Sofela, M.F. Mohd Mustapa et al. · Clinical and Experimental Dermatology · 2021 · 15 citations

Education, Dermatology, Educational Assessment +15